Literature DB >> 19481037

Feline immunodeficiency. ABCD guidelines on prevention and management.

Margaret J Hosie1, Diane Addie, Sándor Belák, Corine Boucraut-Baralon, Herman Egberink, Tadeusz Frymus, Tim Gruffydd-Jones, Katrin Hartmann, Albert Lloret, Hans Lutz, Fulvio Marsilio, Maria Grazia Pennisi, Alan D Radford, Etienne Thiry, Uwe Truyen, Marian C Horzinek.   

Abstract

OVERVIEW: Feline immunodeficiency virus (FIV) is a retrovirus closely related to human immunodeficiency virus. Most felids are susceptible to FIV, but humans are not. Feline immunodeficiency virus is endemic in domestic cat populations worldwide. The virus loses infectivity quickly outside the host and is susceptible to all disinfectants. INFECTION: Feline immunodeficiency virus is transmitted via bites. The risk of transmission is low in households with socially well-adapted cats. Transmission from mother to kittens may occur, especially if the queen is undergoing an acute infection. Cats with FIV are persistently infected in spite of their ability to mount antibody and cell-mediated immune responses. DISEASE SIGNS: Infected cats generally remain free of clinical signs for several years, and some cats never develop disease, depending on the infecting isolate. Most clinical signs are the consequence of immunodeficiency and secondary infection. Typical manifestations are chronic gingivostomatitis, chronic rhinitis, lymphadenopathy, weight loss and immune-mediated glomerulonephritis. DIAGNOSIS: Positive in-practice ELISA results obtained in a low-prevalence or low-risk population should always be confirmed by a laboratory. Western blot is the 'gold standard' laboratory test for FIV serology. PCR-based assays vary in performance. DISEASE MANAGEMENT: Cats should never be euthanased solely on the basis of an FIV-positive test result. Cats infected with FIV may live as long as uninfected cats, with appropriate management. Asymptomatic FIV-infected cats should be neutered to avoid fighting and virus transmission. Infected cats should receive regular veterinary health checks. They can be housed in the same ward as other patients, but should be kept in individual cages. VACCINATION RECOMMENDATIONS: At present, there is no FIV vaccine commercially available in Europe. Potential benefits and risks of vaccinating FIV-infected cats should be assessed on an individual cat basis. Needles and surgical instruments used on FIV-positive cats may transmit the virus to other cats, so strict hygiene is essential.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481037      PMCID: PMC7129779          DOI: 10.1016/j.jfms.2009.05.006

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  59 in total

Review 1.  Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action.

Authors:  W A Tompkins
Journal:  J Interferon Cytokine Res       Date:  1999-08       Impact factor: 2.607

2.  Molecular subtyping of feline immunodeficiency virus from domestic cats in Australia.

Authors:  R K C Kann; M T Kyaw-Tanner; J M Seddon; P R Lehrbach; R J G Zwijnenberg; J Meers
Journal:  Aust Vet J       Date:  2006-04       Impact factor: 1.281

3.  Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses.

Authors:  R A Olmsted; V M Hirsch; R H Purcell; P R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 4.  Feline immunodeficiency virus vaccine: implications for diagnostic testing and disease management.

Authors:  James R Richards
Journal:  Biologicals       Date:  2005-10-28       Impact factor: 1.856

5.  Histologic classification and immunophenotype of lymphosarcomas in cats with naturally and experimentally acquired feline immunodeficiency virus infections.

Authors:  J J Callanan; B A Jones; J Irvine; B J Willett; I A McCandlish; O Jarrett
Journal:  Vet Pathol       Date:  1996-05       Impact factor: 2.221

6.  Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome.

Authors:  N S Zeidner; M H Myles; C K Mathiason-DuBard; M J Dreitz; J I Mullins; E A Hoover
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

7.  Neurologic dysfunctions caused by a molecular clone of feline immunodeficiency virus, FIV-PPR.

Authors:  T R Phillips; O Prospero-Garcia; D W Wheeler; P C Wagaman; D L Lerner; H S Fox; L R Whalen; F E Bloom; J H Elder; S J Henriksen
Journal:  J Neurovirol       Date:  1996-12       Impact factor: 2.643

8.  Long-term clinical observations on feline immunodeficiency virus infected asymptomatic carriers.

Authors:  T Ishida; A Taniguchi; S Matsumura; T Washizu; I Tomoda
Journal:  Vet Immunol Immunopathol       Date:  1992-12       Impact factor: 2.046

Review 9.  Feline immunodeficiency virus infection: an overview.

Authors:  K Hartmann
Journal:  Vet J       Date:  1998-03       Impact factor: 2.688

10.  Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus.

Authors:  Brian J Willett; Elizabeth L McMonagle; Susan Ridha; Margaret J Hosie
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more
  46 in total

1.  Dual-emission fluorescence resonance energy transfer (FRET) real-time PCR differentiates feline immunodeficiency virus subtypes and discriminates infected from vaccinated cats.

Authors:  Chengming Wang; Calvin M Johnson; Sudhir K Ahluwalia; Erfan Chowdhury; Yihang Li; Dongya Gao; Anil Poudel; K Shamsur Rahman; Bernhard Kaltenboeck
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

Review 2.  Feline leukemia virus and feline immunodeficiency virus in Canada: recommendations for testing and management.

Authors:  Susan Little; Dorothee Bienzle; Lisa Carioto; Hugh Chisholm; Elizabeth O'Brien; Margie Scherk
Journal:  Can Vet J       Date:  2011-08       Impact factor: 1.008

3.  Prevalence of feline herpesvirus-1, feline calicivirus, Chlamydia felis, and Bordetella bronchiseptica in a population of shelter cats on Prince Edward Island.

Authors:  Julie Walter; Peter Foley; Carmencita Yason; Raphael Vanderstichel; Anne Muckle
Journal:  Can J Vet Res       Date:  2020-07       Impact factor: 1.310

4.  The first feline immunodeficiency virus from Siberian tigers (Panthera tigris altaica) in northeastern China.

Authors:  Enqi Liu; Liying Ma; Shuping Huang; Dan You; Lijun Guo; Xiang Li; Haitao Xu; Dan Liu; Hongliang Chai; Yajun Wang
Journal:  Arch Virol       Date:  2022-01-22       Impact factor: 2.574

5.  Evaluation of different antiretroviral drug protocols on naturally infected feline immunodeficiency virus (FIV) cats in the late phase of the asymptomatic stage of infection.

Authors:  Nélida V Gómez; Adriana Fontanals; Víctor Castillo; María A Gisbert; Adriana Suraniti; Graciela Mira; Paola B Pisano
Journal:  Viruses       Date:  2012-05-30       Impact factor: 5.048

6.  Anti-Inflammatory Therapy for Feline Immunodeficiency Virus Infection and Associated AIDS-Like Syndrome.

Authors:  Arne Lucas Ten Hoeve; Arden Leander van Arnhem
Journal:  Front Microbiol       Date:  2011-07-19       Impact factor: 5.640

Review 7.  Feline immunodeficiency virus in South America.

Authors:  Bruno M Teixeira; Mitika K Hagiwara; Juliano C M Cruz; Margaret J Hosie
Journal:  Viruses       Date:  2012-03-14       Impact factor: 5.818

Review 8.  Pharmacological inhibition of feline immunodeficiency virus (FIV).

Authors:  Hakimeh Mohammadi; Dorothee Bienzle
Journal:  Viruses       Date:  2012-04-27       Impact factor: 5.048

9.  Comparison of the geographical distribution of feline immunodeficiency virus and feline leukemia virus infections in the United States of America (2000-2011).

Authors:  Bimal K Chhetri; Olaf Berke; David L Pearl; Dorothee Bienzle
Journal:  BMC Vet Res       Date:  2013-01-05       Impact factor: 2.741

10.  Renal alterations in feline immunodeficiency virus (FIV)-infected cats: a natural model of lentivirus-induced renal disease changes.

Authors:  Alessandro Poli; Natasa Tozon; Grazia Guidi; Mauro Pistello
Journal:  Viruses       Date:  2012-08-27       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.